{"filing":{"accession_number":"0001104659-26-089726","cik":"0001333141","ticker":"FMCQF","company_name":"Fresenius Medical Care AG","form":"6-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"tm2620437d2_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1333141/000110465926089726/tm2620437d2_6k.htm"},"events":[{"id":23067,"run_id":20883,"accession_number":"0001104659-26-089726","anchor_item_number":"EX-99.1","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a press release disclosing Fresenius Medical Care's Q2 2026 financial results, including revenue of EUR 4,861 million, operating income growth of 23% (adjusted), and EPS growth of 28% (adjusted). The document explicitly presents quarterly earnings figures, segment performance, cash flow metrics, and reaffirms the FY 2026 outlook—all hallmarks of an earnings release. Material to investors assessing the company's financial performance and strategic progress.","company_name":"Fresenius Medical Care AG","ticker":"FMCQF","filing_date":"2026-08-03","form":"6-K","submitted_at":null,"items":[{"id":23208,"accession_number":"0001104659-26-089726","item_number":"EX-99.1","item_title":"tm2620437d2_ex99-1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a press release disclosing Fresenius Medical Care's Q2 2026 financial results, including revenue of EUR 4,861 million, operating income growth of 23% (adjusted), and EPS growth of 28% (adjusted). The document explicitly presents quarterly earnings figures, segment performance, cash flow metrics, and reaffirms the FY 2026 outlook—all hallmarks of an earnings release. Material to investors assessing the company's financial performance and strategic progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:26:36.126029+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23208,"accession_number":"0001104659-26-089726","item_number":"EX-99.1","item_title":"tm2620437d2_ex99-1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a press release disclosing Fresenius Medical Care's Q2 2026 financial results, including revenue of EUR 4,861 million, operating income growth of 23% (adjusted), and EPS growth of 28% (adjusted). The document explicitly presents quarterly earnings figures, segment performance, cash flow metrics, and reaffirms the FY 2026 outlook—all hallmarks of an earnings release. Material to investors assessing the company's financial performance and strategic progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:26:36.126029+00:00","company_name":"Fresenius Medical Care AG","ticker":"FMCQF","filing_date":"2026-08-03"},{"id":23209,"accession_number":"0001104659-26-089726","item_number":"EX-99.2","item_title":"tm2620437d2_ex99-2.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":true,"confidence":0.95,"reasoning":"This exhibit is a complete interim financial report for the six months ended June 30, 2026, containing a statement of earnings, segment information, balance sheet, cash flow statement, key metrics, and management outlook. The document explicitly states \"COMPLETE OVERVIEW OF THE SECOND QUARTER AND FIRST HALF YEAR 2026\" and includes all standard components of a periodic interim financial report (half-year results), not a discrete event announcement. As a foreign private issuer's interim financial report, it should be classified as periodic_interim and deferred for separate processing.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:26:36.126029+00:00","company_name":"Fresenius Medical Care AG","ticker":"FMCQF","filing_date":"2026-08-03"}]}